Cargando…

SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open-Label Study Using Canakinumab

PURPOSE: To evaluate the effect of systemic interleukin 1β inhibition using canakinumab (Ilaris) on retinal neovascularizations in proliferative diabetic retinopathy. METHODS: Patients with proliferative diabetic retinopathy were enrolled in a prospective uncontrolled pilot study. Canakinumab (150 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stahel, Marc, Becker, Matthias, Graf, Nicole, Michels, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Retina 2016
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747976/ https://www.ncbi.nlm.nih.gov/pubmed/26218500 http://dx.doi.org/10.1097/IAE.0000000000000701

Ejemplares similares

Blockage of interleukin-1β with canakinumab in patients with Covid-19
por: Landi, Lorenza, et al.
Publicado: (2020)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
por: Wons, Juliana, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy
por: Yan, Ai, et al.
Publicado: (2022)

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
por: Lopez-Lopez, F., et al.
Publicado: (2012)

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
por: Gattorno, Marco, et al.
Publicado: (2017)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Proliferative diabetic retinopathy in long-term diabetic patients with and without clinical osteoarthritis
por: Skolik, S A, et al.
Publicado: (2013)

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
por: Aróstegui, JI, et al.
Publicado: (2015)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

A Flow Cytometric Analysis of Vitreous Inflammatory Cells in Patients with Proliferative Diabetic Retinopathy
por: Urbančič, Mojca, et al.
Publicado: (2013)

A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy
por: Yang, Xiaochun, et al.
Publicado: (2016)

Heritability of Proliferative Diabetic Retinopathy
por: Hietala, Kustaa, et al.
Publicado: (2008)

Proliferative diabetic retinopathy in acromegaly
por: Malhotra, Chintan
Publicado: (2010)

Novel therapies for proliferative retinopathies
por: Martinez-Alejo, Juan Manuel, et al.
Publicado: (2022)

Preoperative Intravitreal Conbercept Facilitates Vitrectomy in Proliferative Diabetic Retinopathy: Is Attention Required for the Fellow Eye?
por: Xu, Wei, et al.
Publicado: (2019)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy
por: Chernykh, VV, et al.
Publicado: (2015)

Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
por: Cui, Jinglin, et al.
Publicado: (2018)

Internal Limiting Membrane Flaps for Coexistent Macular Hole and Retinal Detachment in Eyes with Proliferative Diabetic Retinopathy
por: Chen, San-Ni, et al.
Publicado: (2018)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot study
por: Wirth, Magdalena A., et al.
Publicado: (2016)

Growth Factors in Proliferative Diabetic Retinopathy
por: Khan, Zia Ali, et al.
Publicado: (2003)

Candidate Genes for Proliferative Diabetic Retinopathy
por: Petrovič, Daniel
Publicado: (2013)

Predicting Development of Proliferative Diabetic Retinopathy
por: Harris Nwanyanwu, Kristen, et al.
Publicado: (2013)

The Effects of Pleiotrophin in Proliferative Diabetic Retinopathy
por: Zhu, Xuemei, et al.
Publicado: (2015)

Refining vitrectomy for proliferative diabetic retinopathy
por: Chen, San-Ni, et al.
Publicado: (2023)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy
por: Loporchio, Dean F., et al.
Publicado: (2021)

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)

Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population
por: Zhong, Ze-Long, et al.
Publicado: (2012)

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study
por: Generali, Daniele, et al.
Publicado: (2021)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jeaua06n59u1lvjjkcotgbk0eb